See the Complete Neurology Collection →
Supported by educational grants from EMD Serono and Genzyme, a Sanofi Company.
Michael C. Levin, MD, and W. Clay Jackson, MD, DipTh
Early diagnosis of MS is critical for patients to begin disease-modifying therapy as soon as possible. Read this Neurology Report to learn how to apply updated diagnostic criteria to recognize MS in its early stages and to rule out conditions similar to MS using appropriate tests.
0.5 Credit [ See the entire activity ]
Do you tailor your treatment plan for patients with MS according to their disease course and preferred administration method? In this Neurology Report, review the benefits and adverse effects of the available disease-modifying agents for MS and find out how to select appropriate relapse treatment.
Michael C. Levin, MD
Department of Neurology and the MS Clinic and Laboratory of Viral and Demyelinating Disease, University of Tennessee Health Science Center, Memphis
W. Clay Jackson, MD, DipTh
Departments of Family Medicine and Psychiatry, University of Tennessee College of Medicine, Memphis